Published in Gene Therapy Weekly, July 31st, 2003
The company also announced regulatory progress towards starting a Phase I/II trial with MetXia in pancreatic cancer.
MetXia is Oxford BioMedica's leading gene-based cancer therapeutic. The product is based on a highly engineered retrovirus gene delivery system expressing a specific human cytochrome P450 gene. MetXia converts the tumor into a 'drug factory,' enabling increased local production of the antitumor, cytotoxic derivative of the prodrug cyclophosphamide. MetXia is potentially useful in the treatment of all...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.